In contrast to small molecule drugs, which are chemically synthesized, biologics and biosimilars, also known as biotherapeutic drugs, are produced from living organisms such as bacteria, yeast and mammalian cells.
NMR is ideally suited for similarity assessment of biologics and biosimilars. NMR allows for intact protein analysis, enabling structural evaluation of therapeutic drugs without modification, in conditions that are physiologically relevant. Learn more about Bruker’s solutions for Biologics and Biosimilars below.